Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 7747–7749.

https://doi.org/10.1182/blood-2022-167407

Published: 2022

Journal Articles

Prognostic Impact of Persistent Measurable Residual Disease in Patients with Acute Myeloid Leukemia FLT3+ Treated with Intensive Chemotherapy Plus Midostaurin - a Retrospective Study of the Polish Adult Leukemia Group (PALG)

Blood (2022) 140 (Supplement 1): 11836–11837.

https://doi.org/10.1182/blood-2022-170126

Published: 2022

Journal Articles

MEN1703-Mediated PIM Kinases Inhibition Impairs Protumoral and Immunosuppressive Phenotype and Functions of Macrophages in Classical Hodgkin Lymphoma

Maciej Szydlowski, Filip Garbicz, Ewa Kurtz, Justyna Żurańska, Michał Seweryn, Michał Pawlak, Patryk Górniak, Kamil Sokół, Anna Szumera-Ciećkiewicz, Monika Kawecka, Daria Owczarek, Beata Puton, Monika Prochorec-Sobieszek, Daniela Bellarosa, Michał Kurlapski, Jan Zaucha, Paweł Wołkow, Przemyslaw Juszczynski

Blood (2022) 140 (Supplement 1): 6441–6442.

https://doi.org/10.1182/blood-2022-156894

Published: 2022

Journal Articles

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage

Agnieszka Wierzbowska, Agnieszka Pluta, Piotr Stelmach, Marta Anna Sobas, Justyna Rybka, Tomasz Wróbel, Ewa Zarzycka, Witold Prejzner, Jan Zaucha, Andrzej Szczepaniak, Lidia Gil, Sebastian Giebel

Blood (2022) 140 (Supplement 1): 6165–6166.

https://doi.org/10.1182/blood-2022-163109

Published: 2022

Journal Articles

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Kathryn Humphrey, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Ben Byrne, Naseer Qayum, Carmelo Carlo-Stella

Blood (2022) 140 (Supplement 1): 178–180.

https://doi.org/10.1182/blood-2022-157777

Published: 2022

Journal Articles

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

Blood (2022) 140 (Supplement 1): 3206–3207.

https://doi.org/10.1182/blood-2022-166227

Published: 2022

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Kathryn Humphrey, David Perez-Callejo, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Emma Clark, Carmelo Carlo-Stella

Blood (2021) 138 (Supplement 1): 130.

https://doi.org/10.1182/blood-2021-148949

Published: 2021

Journal Articles

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML

Blood (2021) 138 (Supplement 1): 2371.

https://doi.org/10.1182/blood-2021-152273

Published: 2021

Journal Articles

RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation

Blood (2021) 138 (Supplement 1): 1518.

https://doi.org/10.1182/blood-2021-150662

Published: 2021

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Agnieszka Wierzbowska, MDPhD, Agnieszka Pluta, MDPhD, Marta Antonina Libura, MDPhD, Anna Czyz, MDPhD, Sebastian Giebel, MDPhD, Piotr Stelmach, MDPhD, Magdalena Czemerska, MDPhD, Anna Kopinska, MD, Krzysztof Wozniczka, MDPhD, Grzegorz Helbig, MDPhD, Karol Wojcik, MD, Malgorzata Razny, MDPhD, Marta Sobas, MDPhD, Tomasz Wrobel, MDPhD, Andrzej Szczepaniak, MDPhD, Lidia Gil, MDPhD, Alicja Sadowska-Klasa, MD, Jan Zaucha, MDPhD, Tomasz Gromek, MDPhD, Marek Hus, MDPhD, Edyta Cichocka, MDPhD, Janusz Halka, MDPhD, Elzbieta Patkowska, Jolanta Wozniak, PhD, Agata Obara, MD, Beata Blajer-Olszewska, MD, Katarzyna Dulik, MD, Jerzy Holowiecki, MDPhD, Michal Soin, M.Sc., Tadeusz Robak, MDPhD, Nicole M. Cruz, MD, Nuria Mencia-Trinchant, PhD, Pinkal Desai, MDMPH, Sangmin Lee, MD, Michael B. Samuel, MD, Justin D. Kaner, MD, Ellen Ritchie, MD, Monica L. Guzman, PhD, Gail J. Roboz, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140694

Published: 2020

Journal Articles

Hodgkin Lymphoma Reed-Sternberg Cells Induce Immunosuppressive and Pro-Angiogenic Phenotype of Tumor-Associated Macrophages in a Paracrine Manner

Maciej Szydlowski, PhD, Michał Pawlak, PhD, Filip Garbicz, MD, Patryk Górniak, PhD, Justyna Żurańska, PhD, Magdalena Król, PhD, Bartłomiej Taciak, Maciej Białasek, Anna Szumera-Ciećkiewicz, MD PhD, Kamil Sokół, Monika Stańczak, Msc, Daria Owczarek, Monika Prochorec-Sobieszek, MD PhD, Anna Polak, PhD, Emilia Bialopiotrowicz, PhD, Michał Kurlapski, Jan Zaucha, MDPhD, Paweł Wołkow, PhD, Przemyslaw Juszczynski, MD PhD

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-134886

Published: 2020

Journal Articles

The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136544

Published: 2020

Journal Articles

Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group

Blood (2019) 134 (Supplement_1): 5276.

https://doi.org/10.1182/blood-2019-130484

Published: 2019

Journal Articles

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Pashna N. Munshi, MD, Parameswaran Hari, MBBS, MD, David H. Vesole, MD PhD, Artur Jurczyszyn, MD, Jan Zaucha, MD PhD, Omar Davila, Shaji K. Kumar, MD, Nina D. Shah, MD, Muzaffar H. Qazilbash, MD, Anita D'Souza, MDMS

Blood (2019) 134 (Supplement_1): 782.

https://doi.org/10.1182/blood-2019-124804

Published: 2019

Journal Articles

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

Tycel J. Phillips, MD, Stephen D. Smith, MD, Wojciech Jurczak, Tadeusz Robak, MD PhD, Don Stevens, MD, Charles M. Farber, MD PhD, John M. Pagel, MD PhD, Kami J. Maddocks, MD, Ian W. Flinn, MD PhD, Wieslaw W. Jedrzejczak, MD PhD, Andre Goy, MD, Pier Luigi Zinzani, MD, Jan Zaucha, MD PhD, Morton Coleman, MD, Tianling Chen, MD, Sun Ku Lee, PhD, Wei Liang, PhD, Anna Seto, PharmD, Michael Wang, MD

Blood (2018) 132 (Supplement 1): 4144.

https://doi.org/10.1182/blood-2018-99-110617

Published: 2018

Journal Articles

Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen

Mathias J Rummel, MD PhD, Ann Janssens, David MacDonald, MD FRCPC, Mary-Margaret Keating, MD, Jan Zaucha, MD, Jaclyn Davis, MD, Janet Lasher, Nathalie Lobe, Miguel Izquierdo, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 450.

https://doi.org/10.1182/blood-2018-99-114484

Published: 2018

Journal Articles

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Blood (2018) 132 (Supplement 1): 5375.

https://doi.org/10.1182/blood-2018-99-116610

Published: 2018

Journal Articles

Bendamustine, Gemcitabine and Dexamethasone Chemotherapy Is Effective Salvage and Stem-Cell Mobilization Regimen in Patients with Relapsed or Refractory Hodgkin Lymphoma — Early Results of the Polish Lymphoma Research Group Study

Ewa Paszkiewicz-Kozik, Jan Zaucha, MD PhD, Agata Tyczyńska, MD, Marcin Szymanski, MD, Lukasz Targonski, MD, Joanna Drozd-Sokolowska, MD PhD, Elżbieta Wojciechowska-Lampka, MD, Joanna Tajer, MD PhD, Pawel Kurczab, MD, Joanna Romejko-Jarosinska, MD PhD, Michal Osowiecki, MD, Jan Walewski, MD PhD

Blood (2017) 130 (Supplement 1): 4098.

https://doi.org/10.1182/blood.V130.Suppl_1.4098.4098

Published: 2017

Journal Articles

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Johannes Drach, MD, Huiqiang Huang, MD, Olga S Samoilova, MD, Andrew Belch, MD, Charles M. Farber, MD PhD, André Bosly, MD PhD, Jan Novak, MD PhD, Jan Zaucha, MD PhD, Angela Dascalescu, MD PhD, Udomsak Bunworasate, MD, Zvenyslava Masliak, MD PhD, Kateryna Vilchevskaya, MD PhD, Tadeusz Robak, MD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD

Blood (2014) 124 (21): 3064.

https://doi.org/10.1182/blood.V124.21.3064.3064

Published: 2014

Journal Articles

Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia

Douglas Gladstone, MD, Marc Andre, MD PhD, Jan Zaucha, MD PhD, Sarit Assouline, MD MSc, Naresh Bellam, MD MPH, Nicole Cascavilla, MD, Eric Jourdan, MD PhD, Amit Panwalkar, MD, Caterina Patti, MD, Clemens Schulte, MD, Francesco Zaja, MD, Trishna Goswami, MD, Nairouz Elgeioushi, MPH, Katie Streicher, PhD, Haifeng Bao, PhD, David Spaner, MD FRCPC, PhD

Blood (2014) 124 (21): 4472.

https://doi.org/10.1182/blood.V124.21.4472.4472

Published: 2014

NARROW

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Prognostic Impact of Persistent Measurable Residual Disease in Patients with Acute Myeloid Leukemia FLT3+ Treated with Intensive Chemotherapy Plus Midostaurin - a Retrospective Study of the Polish Adult Leukemia Group (PALG)

MEN1703-Mediated PIM Kinases Inhibition Impairs Protumoral and Immunosuppressive Phenotype and Functions of Macrophages in Classical Hodgkin Lymphoma

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML

RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Hodgkin Lymphoma Reed-Sternberg Cells Induce Immunosuppressive and Pro-Angiogenic Phenotype of Tumor-Associated Macrophages in a Paracrine Manner

The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Bendamustine, Gemcitabine and Dexamethasone Chemotherapy Is Effective Salvage and Stem-Cell Mobilization Regimen in Patients with Relapsed or Refractory Hodgkin Lymphoma — Early Results of the Polish Lymphoma Research Group Study

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only